Critical quality attributes in the development of therapeutic nanomedicines toward clinical translation
暂无分享,去创建一个
Mansoor M. Amiji | Amit Singh | Maie S. Taha | Smrithi Padmakumar | M. Amiji | Smrithi Padmakumar | Amit Singh
[1] B. Aksu,et al. QbD guided early pharmaceutical development study: Production of lipid nanoparticles by high pressure homogenization for skin cancer treatment , 2019, International journal of pharmaceutics.
[2] T. Ochiya,et al. Unveiling massive numbers of cancer-related urinary-microRNA candidates via nanowires , 2017, Science Advances.
[3] Jim Nolan,et al. A Quality by Design Approach to Developing and Manufacturing Polymeric Nanoparticle Drug Products , 2016, The AAPS Journal.
[4] Shiladitya Sengupta. Cancer Nanomedicine: Lessons for Immuno-Oncology. , 2017, Trends in cancer.
[5] S. Chitlange,et al. Application of quality by design approach to optimize process and formulation parameters of rizatriptan loaded chitosan nanoparticles , 2015, Journal of advanced pharmaceutical technology & research.
[6] Zoraida P. Aguilar. Targeted Drug Delivery , 2013 .
[7] L. Cardozo,et al. Research and Reports in Urology Dovepress Novel Targeted Bladder Drug-delivery Systems: a Review , 2022 .
[8] S. Nair,et al. Efficacy versus Toxicity - The Ying and Yang in Translating Nanomedicines , 2014 .
[9] H. Maeda,et al. Exploiting the enhanced permeability and retention effect for tumor targeting. , 2006, Drug discovery today.
[10] S. Nair,et al. Long-term drug delivery using implantable electrospun woven polymeric nanotextiles. , 2019, Nanomedicine : nanotechnology, biology, and medicine.
[11] A. Fathi,et al. Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML , 2018, OncoTargets and therapy.
[12] T. Andresen,et al. Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release. , 2005, Progress in lipid research.
[13] T. Xia,et al. Understanding biophysicochemical interactions at the nano-bio interface. , 2009, Nature materials.
[14] L. Kumar,et al. A quality by design approach on polymeric nanocarrier delivery of gefitinib: formulation, in vitro, and in vivo characterization , 2016, International journal of nanomedicine.
[15] Filip Braet,et al. Contribution of high‐resolution correlative imaging techniques in the study of the liver sieve in three‐dimensions , 2007, Microscopy research and technique.
[16] Akihide Arima,et al. Selective detections of single-viruses using solid-state nanopores , 2018, Scientific Reports.
[17] S. Ramakrishna,et al. Bredigite Reinforced Electrospun Nanofibers for Bone Tissue Engineering , 2019, Materials Today: Proceedings.
[18] H. von Briesen,et al. Adsorption of obidoxime onto human serum albumin nanoparticles: Drug loading, particle size and drug release , 2010, Journal of microencapsulation.
[19] Michael J Heller,et al. Integrated Analysis of Exosomal Protein Biomarkers on Alternating Current Electrokinetic Chips Enables Rapid Detection of Pancreatic Cancer in Patient Blood. , 2018, ACS nano.
[20] Guo-qiang Chen,et al. Polymer nanoparticles. , 2011, Progress in molecular biology and translational science.
[21] H. Fessi,et al. Polymeric nanoparticles for oral delivery of drugs and vaccines: a critical evaluation of in vivo studies. , 2005, Critical reviews in therapeutic drug carrier systems.
[22] Chao Zhang,et al. Immune responses to vaccines delivered by encapsulation into and/or adsorption onto cationic lipid-PLGA hybrid nanoparticles. , 2016, Journal of controlled release : official journal of the Controlled Release Society.
[23] L. Weiss,et al. The role of the sinus wall in the passage of erythrocytes through the spleen. , 1973, Blood.
[24] Thomas J Webster,et al. Nanomedicine: what’s in a definition? , 2006, International journal of nanomedicine.
[25] O. Galibin,et al. Granzyme B Functionalized Nanoparticles Targeting Membrane Hsp70-Positive Tumors for Multimodal Cancer Theranostics. , 2019, Small.
[26] D. Menon,et al. Impact of poly(lactic-co-glycolic acid) nanoparticle surface charge on protein, cellular and haematological interactions. , 2015, Colloids and surfaces. B, Biointerfaces.
[27] Bo Yan,et al. Surface Charge Controls the Suborgan Biodistributions of Gold Nanoparticles. , 2016, ACS nano.
[28] Engineered Nanoparticulate Drug Delivery Systems: The Next Frontier for Oral Administration? , 2012, The AAPS Journal.
[29] Thierry Bastogne,et al. Quality-by-design of nanopharmaceuticals - a state of the art. , 2017, Nanomedicine : nanotechnology, biology, and medicine.
[30] D. Raucher,et al. Polymer-Based Prodrugs: Improving Tumor Targeting and the Solubility of Small Molecule Drugs in Cancer Therapy , 2015, Molecules.
[31] Ute Hoffmann,et al. Drug Delivery Engineering Principles For Drug Therapy , 2016 .
[32] N. Vrana,et al. Use of Nanoparticles in Tissue Engineering and Regenerative Medicine , 2019, Front. Bioeng. Biotechnol..
[33] Huile Gao,et al. The impact of protein corona on the behavior and targeting capability of nanoparticle‐based delivery system , 2018, International journal of pharmaceutics.
[34] H. Ueno,et al. A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation , 2007, British Journal of Cancer.
[35] Lisa A. DeLouise,et al. Nanoparticle-Enabled Transdermal Drug Delivery Systems for Enhanced Dose Control and Tissue Targeting , 2016, Molecules.
[36] C. Moonen,et al. Pharmacological and physical vessel modulation strategies to improve EPR-mediated drug targeting to tumors. , 2017, Advanced drug delivery reviews.
[37] A. Shukla,et al. Tamoxifen-loaded novel liposomal formulations: evaluation of anticancer activity on DMBA-TPA induced mouse skin carcinogenesis , 2012, Journal of drug targeting.
[38] Hua Ai,et al. Micellar carriers based on block copolymers of poly(ε-caprolactone) and poly(ethylene glycol) for doxorubicin delivery , 2004 .
[39] Susan Hua,et al. Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization , 2018, Front. Pharmacol..
[40] Robert Langer,et al. Self-assembled lipid--polymer hybrid nanoparticles: a robust drug delivery platform. , 2008, ACS nano.
[41] A. Albertsson,et al. Achieving Micelle Control through Core Crystallinity , 2013, Biomacromolecules.
[42] Rita Ambrus,et al. Development of oral lyophilisates containing meloxicam nanocrystals using QbD approach , 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[43] Maie S. Taha,et al. Sustained delivery of carfilzomib by tannic acid-based nanocapsules helps develop antitumor immunity. , 2019, Nano letters.
[44] Kanyi Pu,et al. Metabolizable Semiconducting Polymer Nanoparticles for Second Near‐Infrared Photoacoustic Imaging , 2019, Advanced materials.
[45] Morteza Mahmoudi,et al. Biological Identity of Nanoparticles In Vivo: Clinical Implications of the Protein Corona. , 2017, Trends in biotechnology.
[46] Yu Qin,et al. Targeted Codelivery of an Antigen and Dual Agonists by Hybrid Nanoparticles for Enhanced Cancer Immunotherapy. , 2019, Nano letters.
[47] S. Nair,et al. Intraperitoneal chemotherapy for ovarian cancer using sustained-release implantable devices , 2018, Expert opinion on drug delivery.
[48] Neil Desai,et al. Challenges in Development of Nanoparticle-Based Therapeutics , 2012, The AAPS Journal.
[49] G. Geis,et al. Efficacy and Upper GI Safety of Diclofenac/Misoprostol, Piroxicam and Naproxen in Patients with Osteoarthritis , 2012, Drugs.
[50] Leaf Huang,et al. Pharmacokinetics and biodistribution of nanoparticles. , 2008, Molecular pharmaceutics.
[51] Xiaoping Yang,et al. Effects of Particle Hydrophobicity, Surface Charge, Media pH Value and Complexation with Human Serum Albumin on Drug Release Behavior of Mitoxantrone-Loaded Pullulan Nanoparticles , 2015, Nanomaterials.
[52] Diane J Burgess,et al. A quality by design (QbD) case study on liposomes containing hydrophilic API: I. Formulation, processing design and risk assessment. , 2011, International journal of pharmaceutics.
[53] Antonio P. Costa,et al. Application of quality by design to formulation and processing of protein liposomes. , 2012, International journal of pharmaceutics.
[54] Marina A Dobrovolskaia,et al. Pre-clinical immunotoxicity studies of nanotechnology-formulated drugs: Challenges, considerations and strategy. , 2015, Journal of controlled release : official journal of the Controlled Release Society.
[55] Anwarul Hasan,et al. Nanoparticles in tissue engineering: applications, challenges and prospects , 2018, International journal of nanomedicine.
[56] Karen C Liu,et al. Extracellular stability of nanoparticulate drug carriers , 2014, Archives of pharmacal research.
[57] P. Couvreur,et al. Translation of nanomedicines from lab to industrial scale synthesis: The case of squalene-adenosine nanoparticles. , 2019, Journal of controlled release : official journal of the Controlled Release Society.
[58] Chunmao Han,et al. Silver nanoparticle loaded collagen/chitosan scaffolds promote wound healing via regulating fibroblast migration and macrophage activation , 2017, Scientific Reports.
[59] L. Treccani,et al. Modulation of Silica Nanoparticle Uptake into Human Osteoblast Cells by Variation of the Ratio of Amino and Sulfonate Surface Groups: Effects of Serum , 2015, ACS applied materials & interfaces.
[60] Assaf Shapira,et al. Nanoengineering gold particle composite fibers for cardiac tissue engineering. , 2013, Journal of materials chemistry. B.
[61] Hang Xing,et al. A spherical nucleic acid-based two-photon nanoprobe for RNase H activity assay in living cells and tissues. , 2019, Nanoscale.
[62] M. Bawendi,et al. Renal clearance of quantum dots , 2007, Nature Biotechnology.
[63] Yoon Yeo,et al. Particle engineering for intracellular delivery of vancomycin to methicillin‐resistant Staphylococcus aureus (MRSA)‐infected macrophages , 2017, Journal of controlled release : official journal of the Controlled Release Society.
[64] K. Landfester,et al. Pre-adsorption of antibodies enables targeting of nanocarriers despite a biomolecular corona , 2018, Nature Nanotechnology.
[65] Philip M. Kelly,et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. , 2013, Nature nanotechnology.
[66] L. Nath,et al. Polymer-Drug Conjugates: Novel Carriers for Cancer Chemotherapy , 2018, Polymer-Plastics Technology and Materials.
[67] A. R. Kulkarni,et al. Biodegradable polymeric nanoparticles as drug delivery devices. , 2001, Journal of controlled release : official journal of the Controlled Release Society.
[68] H. Takeuchi,et al. Preparation of bromfenac-loaded liposomes modified with chitosan for ophthalmic drug delivery and evaluation of physicochemical properties and drug release profile , 2013 .
[69] G. Acharya,et al. Therapeutic Applications of Polymeric Materials , 2017 .
[70] Tal Dvir,et al. Coiled fiber scaffolds embedded with gold nanoparticles improve the performance of engineered cardiac tissues. , 2014, Nanoscale.
[71] I. Zuhorn,et al. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. , 2004, The Biochemical journal.
[72] Chien‐Ho Chen,et al. Development of mutlifunctional nanoparticles self-assembled from trimethyl chitosan and fucoidan for enhanced oral delivery of insulin. , 2019, International journal of biological macromolecules.
[73] Stefan Tenzer,et al. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. , 2013, Nature nanotechnology.
[74] Q. Ain,et al. Nanopharmaceuticals: A Boon to the Brain-Targeted Drug Delivery , 2019, Pharmaceutical Formulation Design - Recent Practices.
[75] Hak Soo Choi,et al. Renal Clearance of Nanoparticles , 2009 .
[76] Shaobing Zhou,et al. Multifunctional nanoplatforms for subcellular delivery of drugs in cancer therapy , 2020 .
[77] Diane J Burgess,et al. A quality by design (QbD) case study on liposomes containing hydrophilic API: II. Screening of critical variables, and establishment of design space at laboratory scale. , 2012, International journal of pharmaceutics.
[78] R. Amal,et al. Nanoparticle-protein corona complexes govern the biological fates and functions of nanoparticles. , 2014, Journal of materials chemistry. B.
[79] Hiroshi Maeda,et al. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. , 2015, Advanced drug delivery reviews.
[80] J. DeSimone,et al. Nanoparticle surface charge impacts distribution, uptake and lymph node trafficking by pulmonary antigen-presenting cells. , 2016, Nanomedicine : nanotechnology, biology, and medicine.
[81] M Dunne,et al. Influence of particle size and dissolution conditions on the degradation properties of polylactide-co-glycolide particles. , 2000, Biomaterials.
[82] Vivek Agrahari,et al. Facilitating the translation of nanomedicines to a clinical product: challenges and opportunities. , 2018, Drug discovery today.
[83] N. Mabbott,et al. Progress in Molecular Biology and Translational Science , 2017 .
[84] Hemant K.S. Yadav,et al. Polymer-Based Nanomaterials for Drug-Delivery Carriers , 2019, Nanocarriers for Drug Delivery.
[85] Huile Gao,et al. Progress and perspectives on targeting nanoparticles for brain drug delivery , 2016, Acta pharmaceutica Sinica. B.
[86] Ho-Yyoung Lee,et al. Polymer micelle formulation for the proteasome inhibitor drug carfilzomib: Anticancer efficacy and pharmacokinetic studies in mice , 2017, PloS one.
[87] Pilhan Kim,et al. Quinic Acid-Conjugated Nanoparticles Enhance Drug Delivery to Solid Tumors via Interactions with Endothelial Selectins. , 2018, Small.
[88] S. Mitragotri,et al. Nanoparticles in the clinic , 2016, Bioengineering & translational medicine.
[89] M. Mahmoudi,et al. Bypassing Protein Corona Issue on Active Targeting: Zwitterionic Coatings Dictate Specific Interactions of Targeting Moieties and Cell Receptors. , 2016, ACS applied materials & interfaces.
[90] A. J. Tavares,et al. Analysis of nanoparticle delivery to tumours , 2016 .
[91] K. Sandeep,et al. Liposomes for Drug Delivery , 2017 .
[92] E. Miele,et al. Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer , 2009, International journal of nanomedicine.
[93] Samir Mitragotri,et al. Nanoparticles in the clinic: An update , 2019, Bioengineering & translational medicine.
[94] Iseult Lynch,et al. The evolution of the protein corona around nanoparticles: a test study. , 2011, ACS nano.
[95] S. Yusuf,et al. Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation , 2007, International journal of nanomedicine.
[96] Diane J Burgess,et al. Quality by Design approach to spray drying processing of crystalline nanosuspensions. , 2014, International journal of pharmaceutics.
[97] R. Marotta,et al. Enhanced Intra-Liposomal Metallic Nanoparticle Payload Capacity Using Microfluidics Assisted Self-Assembly. , 2019, Langmuir : the ACS journal of surfaces and colloids.
[98] Jianjun Cheng,et al. Paclitaxel-initiated, controlled polymerization of lactide for the formulation of polymeric nanoparticulate delivery vehicles. , 2008, Angewandte Chemie.
[99] Wei Lu,et al. Synergistic triple-combination therapy with hyaluronic acid-shelled PPy/CPT nanoparticles results in tumor regression and prevents tumor recurrence and metastasis in 4T1 breast cancer. , 2019, Biomaterials.
[100] D. Waxman,et al. Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance. , 2015, Cancer letters.
[101] Rachel A. Kudgus,et al. Intrinsic Therapeutic Applications of Noble Metal Nanoparticles: Past, Present and Future , 2012 .
[102] David J. Mooney,et al. Oligolysine-based coating protects DNA nanostructures from low-salt denaturation and nuclease degradation , 2017, Nature Communications.
[103] Naresh Pavurala,et al. Enhanced dissolution of poorly soluble antiviral drugs from nanoparticles of cellulose acetate based solid dispersion matrices , 2017, Asian journal of pharmaceutical sciences.
[104] A. Buzaid,et al. Phase II trial of doxil for patients with metastatic melanoma refractory to frontline therapy. , 1999, Oncology reports.
[105] M. Mahmoudi,et al. Superparamagnetic iron oxide nanoparticle for in vivo molecular and cellular imaging , 2014 .
[106] D. Pinjari,et al. Scale-Up Technologies for Advanced Nanomaterials for Green Energy , 2018 .
[107] J. Ulmer,et al. Induction of Potent Immune Responses by Cationic Microparticles with Adsorbed Human Immunodeficiency Virus DNA Vaccines , 2001, Journal of Virology.
[108] C. Jérôme,et al. Nanoparticles in biomedical imaging , 2013 .
[109] Eric Pridgen,et al. Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles , 2008, Molecular pharmaceutics.
[110] S. Mitragotri,et al. Delivery of Nanoparticles and Macromolecules across the Blood–Brain Barrier , 2020, Advanced Therapeutics.
[111] B. Dahlbäck,et al. The nanoparticle protein corona formed in human blood or human blood fractions , 2017, PloS one.
[112] Xinrong Liu,et al. Dual-Ligand Modification of PEGylated Liposomes Used for Targeted Doxorubicin Delivery to Enhance Anticancer Efficacy , 2019, AAPS PharmSciTech.
[113] Min-Soo Kim,et al. Quality by design: screening of critical variables and formulation optimization of Eudragit E nanoparticles containing dutasteride , 2013, Archives of pharmacal research.
[114] Edina Pallagi,et al. Application of the QbD-based approach in the early development of liposomes for nasal administration. , 2019, International journal of pharmaceutics.
[115] Sara Soares,et al. Nanomedicine: Principles, Properties, and Regulatory Issues , 2018, Front. Chem..
[116] Hanne Mørck Nielsen,et al. High loading efficiency and sustained release of siRNA encapsulated in PLGA nanoparticles: quality by design optimization and characterization. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[117] Y. Bae,et al. Polymer Micelle Formulations of Proteasome Inhibitor Carfilzomib for Improved Metabolic Stability and Anticancer Efficacy in Human Multiple Myeloma and Lung Cancer Cell Lines , 2015, The Journal of Pharmacology and Experimental Therapeutics.
[118] A. Baras,et al. Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Non–Muscle-Invasive Bladder Cancer , 2017, Clinical Cancer Research.
[119] H. Valizadeh,et al. Solid Lipid Nanoparticles and Nanostructured Lipid Carriers: Structure, Preparation and Application. , 2015, Advanced pharmaceutical bulletin.
[120] Donald R Paul,et al. Effects of Structural Order on Barrier Properties , 1990 .
[121] A. Kabanov,et al. Polymer micelles with cross-linked polyanion core for delivery of a cationic drug doxorubicin. , 2009, Journal of controlled release : official journal of the Controlled Release Society.
[122] Y. Barenholz,et al. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. , 1993, Biochimica et biophysica acta.
[123] Xiaoyuan Chen,et al. Stimuli-Responsive Programmed Specific Targeting in Nanomedicine. , 2016, ACS nano.
[124] Wenbin Lin,et al. Are high drug loading nanoparticles the next step forward for chemotherapy? , 2012, Nanomedicine.
[125] Eleonore Fröhlich,et al. The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles , 2012, International journal of nanomedicine.
[126] Meghana Rawal,et al. Quality-by-Design Concepts to Improve Nanotechnology-Based Drug Development , 2019, Pharmaceutical Research.
[127] Leaf Huang,et al. Lipid nanoparticles for gene delivery. , 2014, Advances in genetics.
[128] S. Talegaonkar,et al. Potential of Lipid Nanoparticles (SLNs and NLCs) in Enhancing Oral Bioavailability of Drugs with Poor Intestinal Permeability , 2019, AAPS PharmSciTech.
[129] Jihye Park,et al. 3D Long-Range Triplet Migration in a Water-Stable Metal-Organic Framework for Upconversion-Based Ultralow-Power in Vivo Imaging. , 2018, Journal of the American Chemical Society.
[130] Ze Lu,et al. Paclitaxel-Loaded Gelatin Nanoparticles for Intravesical Bladder Cancer Therapy , 2004, Clinical Cancer Research.
[131] U. Fuhr,et al. Pharmacokinetics of intravesical versus oral oxybutynin in healthy adults: results of an open label, randomized, prospective clinical study. , 2013, The Journal of urology.
[132] F. Muggia,et al. A phase II study of Doxil (liposomal doxorubicin): lack of activity in poor prognosis soft tissue sarcomas. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[133] T. Webster,et al. Advancements in the oral delivery of Docetaxel: challenges, current state-of-the-art and future trends , 2018, International journal of nanomedicine.
[134] Maryam Tabrizian,et al. Protein release kinetics for core-shell hybrid nanoparticles based on the layer-by-layer assembly of alginate and chitosan on liposomes. , 2008, Biomaterials.
[135] Samir Mitragotri,et al. Challenges associated with Penetration of Nanoparticles across Cell and Tissue Barriers: A Review of Current Status and Future Prospects. , 2014, Nano today.
[136] Pengju Pan,et al. Controlled co‐delivery of hydrophilic and hydrophobic drugs from thermosensitive and crystallizable copolymer nanoparticles , 2016 .
[137] T. Park,et al. Biodegradable polymeric micelles composed of doxorubicin conjugated PLGA-PEG block copolymer. , 2001, Journal of controlled release : official journal of the Controlled Release Society.
[138] R. Mcgarry,et al. An in vitro assessment of liposomal topotecan simulating metronomic chemotherapy in combination with radiation in tumor-endothelial spheroids , 2015, Scientific Reports.
[139] Yaping Li,et al. Stimuli-Responsive Nanomedicines for Overcoming Cancer Multidrug Resistance , 2018, Theranostics.
[140] M. Dokukin,et al. Ultrabright fluorescent cellulose acetate nanoparticles for imaging tumors through systemic and topical applications. , 2019, Materials today.
[141] Dan Peer,et al. Progress and challenges towards targeted delivery of cancer therapeutics , 2018, Nature Communications.
[142] M. Kohl,et al. Interaction of Nanoparticles With Biomolecules, Protein, Enzymes, and Its Applications , 2018 .
[143] Jian Yang,et al. Fluorescence imaging enabled poly(lactide-co-glycolide). , 2016, Acta biomaterialia.
[144] G. L. Kumar. FDA-Approved Targeted Therapies in Oncology , 2018, Predictive Biomarkers in Oncology.
[145] Mansoor M Amiji,et al. Multi-functional polymeric nanoparticles for tumour-targeted drug delivery , 2006, Expert opinion on drug delivery.
[146] B. Sarmento,et al. Delivering amoxicillin at the infection site – a rational design through lipid nanoparticles , 2019, International journal of nanomedicine.
[147] Bingxiang Zhang,et al. The tumor-targeting core-shell structured DTX-loaded PLGA@Au nanoparticles for chemo-photothermal therapy and X-ray imaging. , 2015, Journal of controlled release : official journal of the Controlled Release Society.
[148] N. Damodharan,et al. Lipid nanoparticles: A challenging approach for oral delivery of BCS Class-II drugs , 2018, Future Journal of Pharmaceutical Sciences.
[149] Y. Mao,et al. Brain-targeted drug delivery by manipulating protein corona functions , 2019, Nature Communications.
[150] Hatem Fessi,et al. Comparative scale-up of three methods for producing ibuprofen-loaded nanoparticles. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[151] O. Farokhzad,et al. Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release. , 2016, Chemical reviews.
[152] Christine Vauthier,et al. Characterization of nanomedicines: A reflection on a field under construction needed for clinical translation success , 2018, Journal of controlled release : official journal of the Controlled Release Society.
[153] Sajini Vadukumpully,et al. Penetration of gold nanoparticles across the stratum corneum layer of thick-Skin. , 2017, Journal of dermatological science.
[154] B. Michniak-Kohn,et al. Polymeric nanoparticles-based topical delivery systems for the treatment of dermatological diseases. , 2013, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.
[155] Rajesh Singh,et al. Nanoparticle-based targeted drug delivery. , 2009, Experimental and molecular pathology.
[156] C. van Nostrum,et al. Therapeutic Nanomedicine: Cross linked micelles with transiently linked drugs – a versatile drug delivery system , 2010 .
[157] S. Ibrić,et al. Optimization of formulation and process parameters for the production of carvedilol nanosuspension by wet media milling. , 2018, International journal of pharmaceutics.
[158] Yali Liang. DRUG RELEASE AND PHARMACOKINETIC PROPERTIES OF LIPOSOMAL DB-67 , 2010 .
[159] Xiaoxiao Cai,et al. Independent effect of polymeric nanoparticle zeta potential/surface charge, on their cytotoxicity and affinity to cells , 2015, Cell proliferation.
[160] Hisataka Kobayashi,et al. Real-time optical imaging using quantum dot and related nanocrystals. , 2010, Nanomedicine.
[161] J. Goh,et al. Growth factor delivery through electrospun nanofibers in scaffolds for tissue engineering applications. , 2009, Journal of biomedical materials research. Part A.
[162] Sang Kyu Kwak,et al. Cloaking nanoparticles with protein corona shield for targeted drug delivery , 2018, Nature Communications.
[163] P. Soon-Shiong,et al. SPARC Expression Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head and Neck Cancer Patients. , 2009, Translational oncology.
[164] Rubel Chakravarty,et al. Radiolabeled inorganic nanoparticles for positron emission tomography imaging of cancer: an overview. , 2017, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....
[165] Xiaoyuan Chen,et al. Polysaccharide‐Based Controlled Release Systems for Therapeutics Delivery and Tissue Engineering: From Bench to Bedside , 2018, Advanced science.
[166] Kinam Park. The beginning of the end of the nanomedicine hype. , 2019, Journal of controlled release : official journal of the Controlled Release Society.
[167] V. Torchilin,et al. Lipid-chitosan hybrid nanoparticles for controlled delivery of cisplatin , 2019, Drug delivery.
[168] S. Adams,et al. Polyethylene Glycol Nephrotoxicity Secondary to Prolonged High-Dose Intravenous Lorazepam , 1995, The Annals of pharmacotherapy.
[169] F. Ballet. Hepatic circulation: Potential for therapeutic intervention , 1990, Pharmacology & Therapeutics.
[170] Libo Li,et al. Molecular Understanding of the Penetration of Functionalized Gold Nanoparticles into Asymmetric Membranes. , 2017, Langmuir : the ACS journal of surfaces and colloids.
[171] Peter L. Irwin,et al. Antibacterial Activity and Mechanism of Action of Zinc Oxide Nanoparticles against Campylobacter jejuni , 2011, Applied and Environmental Microbiology.
[172] M. Uesaka,et al. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. , 2011, Nature nanotechnology.
[173] Kai Ling,et al. Effect of Pullulan Nanoparticle Surface Charges on HSA Complexation and Drug Release Behavior of HSA-Bound Nanoparticles , 2012, PloS one.
[174] S. Nair,et al. Effect of formulation parameters on pharmacokinetics, pharmacodynamics, and safety of diclofenac nanomedicine , 2019, Drug Delivery and Translational Research.
[175] G. Turco,et al. Nano-composite scaffolds for bone tissue engineering containing silver nanoparticles: preparation, characterization and biological properties , 2013, Journal of Materials Science: Materials in Medicine.
[176] Mauro Ferrari,et al. Principles of nanoparticle design for overcoming biological barriers to drug delivery , 2015, Nature Biotechnology.
[177] G. Cevc. Lipid vesicles and other colloids as drug carriers on the skin. , 2004, Advanced drug delivery reviews.
[178] M. Jaafari,et al. The influence of phospholipid on the physicochemical properties and anti-tumor efficacy of liposomes encapsulating cisplatin in mice bearing C26 colon carcinoma. , 2014, International journal of pharmaceutics.
[179] J. Guan,et al. Enhanced immunocompatibility of ligand-targeted liposomes by attenuating natural IgM absorption , 2018, Nature Communications.
[180] M. Amiji,et al. The role of surface chemistry in serum protein corona-mediated cellular delivery and gene silencing with lipid nanoparticles. , 2019, Nanoscale.
[181] C. van Nostrum,et al. Glucocorticoid-loaded core-cross-linked polymeric micelles with tailorable release kinetics for targeted therapy of rheumatoid arthritis. , 2012, Angewandte Chemie.
[182] Morteza Mahmoudi,et al. Personalized protein corona on nanoparticles and its clinical implications. , 2017, Biomaterials science.
[183] R. Narayan,et al. A top-down technique to improve the solubility and bioavailability of aceclofenac: in vitro and in vivo studies , 2017, International journal of nanomedicine.
[184] Juan J. Giner-Casares,et al. Inorganic nanoparticles for biomedicine: where materials scientists meet medical research , 2016 .
[185] M. Radwan. In Vitro Evaluation of Polyisobutylcyanoacrylate Nanoparticles as a Controlled Drug Carrier for Theophylline , 1995 .
[186] Rassoul Dinarvand,et al. Protein corona variation in nanoparticles revisited: A dynamic grouping strategy. , 2019, Colloids and surfaces. B, Biointerfaces.
[187] Kai Xu,et al. Establishing a GMP manufacturing site for nanoparticles , 2007 .
[188] Dimitrios J. Giliopoulos,et al. Evaluating the effects of crystallinity in new biocompatible polyester nanocarriers on drug release behavior , 2011, International journal of nanomedicine.
[189] Kristofer J. Thurecht,et al. Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date , 2016, Pharmaceutical Research.